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Abstract
BACKGROUND: Anemia is one of the most common complications in end-stage renal disease (ESRD) patients. 
Hepcidin is a hormone that regulates iron homeostasis in patients with ESRD. Carnitine deficiency is commonly seen 
in hemodialysis (HD) patients. 
AIM: This study aimed to investigate the relationship between hepcidin and inflammatory and other anemia markers 
in children with ESRD and to evaluate the association of carnitine deficiency with anemia in these patients.
SUBJECTS AND METHODS: Thirty pediatric patients with ESRD undergoing HD, and thirty healthy, age- and sex-
matched children served as controls were included in the study. Serum levels hepcidin, iron status, high-sensitivity 
C-reactive protein, and total carnitine were measured.
RESULTS: Statistically significant increases in serum levels of hepcidin (100.7 ± 0.99 ng\ml vs. 77.43 ± 0.8 ng\ml, 
p = 0.000), was found in HD children as compared to healthy controls. Statistically significant increase in serum 
levels of hs-CRP (3.94 ± 0.19 mg/l vs. 1.36 ± 0.07 mg/l, p = 0.04) was found in HD children as compared to 
healthy controls. However, serum levels of carnitine (29.59 ± 2.46 μmol/L vs. 36 ± 2.39 μmol/L, p = 0.000) showed 
statistically significant decreases in HD children as compared to healthy controls positive correlation was found 
between hepcidin and hs-CRP (r = 0.059, p = 0.042). Furthermore, a positive correlation was present between serum 
carnitine levels and serum iron levels (r = 0.651, p = 0.042).
CONCLUSION: Serum hepcidin may be a more useful biomarker of functional iron deficiency in children on HD. The 
efficacy of carnitine treatment for children on HD with carnitine deficiency and its effect on anemia needs to be studied.
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Introduction
Anemia is one of the most significant leading 
factors of progression of chronic kidney disease (CKD) 
to end-stage renal disease (ESRD) [1], [2]. Active blood 
loss, hemoglobinopathies, aluminum overload, and 
hypothyroidism are leading factors of anemia in patients 
with ESRD [3]. In addition, anemia is exaggerated 
by oxidative damage of RBCs membrane in chronic 
hemodialysis (HD) patients which shorten erythrocytes 
lifespan [4]. The inflammatory mechanisms result in 
oxidative stress which in turn participates in anemia 
of ESRD patients. Depletion of redox capacity with 
membrane structural deformity and decreased life span 
of erythrocytes is tagged as mechanisms. This, in turn, 
increases the production of hepcidin [5].
Hepcidin (a 2.7-kD peptide) is a hormone that 
binds to ferroportin on the cell wall and diminishes 
expression of iron transport protein transferrin and 
induces erythropoietin resistance, so it inhibits intestinal 
absorption and mobilization of iron stores  [6], [7]. Induction 
of ferroportin degradation and increase intracellular iron 
stores is a known function of hepcidin. Consequently, 
H-ferritin, an iron-binding ferroxidase with cytoprotective 
function is induced [8]. Restoration of iron homeostasis 
induced by hepcidin is accompanied by reduced reactive 
oxygen species, apoptosis, and inflammation and 
approximately 70% improvement of renal function after 
ischemic renal injury [9].
High levels of inflammatory markers are 
associated with erythropoiesis-stimulating agents 
(ESAs) resistance in CKD patients [10]. C-reactive 
protein (CRP) is the gold standard micro-inflammatory 
marker in HD that predicts mortality. Its level significantly 
rises in comparison with other acute-phase proteins, 
considering it a reliable tool in clinical evaluation [11].
Hepcidin levels raise more when patients with 
HD or peritoneal dialysis, because they are exposed 
to intermittent infections and exposure of blood to 
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foreign materials such as catheters and dialysis 
membranes [12]. The peptide level declines during 
HD because it is cleared through the membrane [13]. 
A rebound of hepcidin concentrations happens within 
an hour after finishing dialysis due to the high rate of its 
synthesis [14]. Iron requirements increase during HD 
because of blood loss from discarded residual blood in 
the dialysis equipment, from the hemorrhagic effects 
of anticoagulation, and from the blood needed for the 
frequent laboratory examinations [15], [16].
Carnitine is a low-molecular-weight compound 
synthesized in the kidney, liver, and brain. It can also be 
obtained from the diet [17]. Carnitine is an essential amino-
acid derivative having vital roles in fatty-acid metabolism 
in cardiac muscle and skeletal muscle [18]. Carnitine is 
present in two forms in the body, acylcarnitine, and free 
carnitine, and the sum of them is defined as total carnitine 
[19]. Free carnitine binds to an acyl residue and converted 
to acylcarnitine. In addition, acylcarnitine functions as 
a transporter of fatty acids to mitochondria and as a 
scavenger of excess and harmful acyl residues in cells 
[20]. It has a significant function in organizing energetic 
substrates flow and their balance through the cell wall. 
The nutritional status of HD patients is positively affected 
by carnitine by enhancing a positive protein balance, and 
by reducing insulin resistance and chronic inflammation 
[18]. Carnitine is vital for RBCs to perform their metabolic 
function in renal anemia [19] that can have a negative 
impact on erythrocyte production and survival [20]. 
Carnitine deficiency is reported to be associated with 
several pathological conditions, including cardiac 
dysfunction, muscle weakness and anemia. Therefore, 
it is important to promptly detect carnitine deficiency 
and ensure appropriate carnitine supplementation in 
patients on HD [20] this study aimed to investigate the 
relationship between hepcidin and inflammatory and other 
anemia markers children with ESRD and to evaluate the 
association of carnitine deficiency with anemia in these 
patients.
Subjects and Methods
Thirty children with ESRD undergoing HD, at 
the HD unit of the Centre of Pediatric Nephrology and 
Transplantation, Children’s Hospital, Cairo University, 
were investigated. Children on regular HD treatment for 
not <4 months, using bicarbonate dialysate, and free 
from apparent acute illness were included in the current 
study. Children with malignancies and active infectious 
disease, those who had been hospitalized or had 
undergone surgery or renal transplantation during the 3 
months before the study were excluded from the study. 
All patients were dialyzed using a polysulfone dialyzer, 
with a bicarbonate dialysate, using a blood flow rate 
of 80–150 ml/min and a dialysate flow rate of 500 ml/
min. Each patient was dialyzed 3 times per-week using 
polysulfone membranes. The dialysate fluids were 
prepared from concentrated salt solutions and from 
bicarbonate powder in sealed containers.
Thirty healthy, age- and sex-matched 
children were recruited from the pediatric clinic of 
the National Research Centre (NRC) to serve as 
controls. A full history was obtained from all the 
patients, and all of them underwent a thorough 
clinical examination. Written consent was obtained 
from the parents of each participant. The study was 
approved by the Ethical Committee of the NRC in 
Egypt (ID = 1001008, 2015).
Blood sampling
Peripheral venous blood samples were 
withdrawn from all subjects after overnight fast and 
in HD patients before the session of dialysis. After 
centrifugation at 3500 rpm at 4°C for 15 min, sera were 
separated and stored at –80°C until assayed.
Biochemical analysis
Serum levels of iron, ferritin, total iron-binding 
capacity (TIBC), hemoglobin, and albumin (ALB) 
were measured for all participants using an automatic 
biochemistry analyzer (Olympus America Inc., Center 
Valley, Pennsylvania, USA). The determination of high 
sensitivity CRP (hsCRP) in serum was performed by 
a solid-phase chemiluminescent immunometric assay 
(Immulite/Immulite 1000; Siemens Medical Solution 
Diagnostics, Eschborn, Germany). Serum levels of 
hepcidin prohormone were measured using enzyme-linked 
immunosorbent assay (Flughafenstrasse 52aD-2233 
Hamburg, Germany [ELISA] IBL International GMBH).
Quantitative evaluation of serum total carnitine 
level by rapid liquid chromatography-electrospray 
tandem mass spectrometry (MS): To 20 μL of a 
serum sample, 300 μL of an internal standard solution 
was added containing 3.3 μmol/L 2H3-l-carnitine 
in acetonitrile to precipitate the serum protein in an 
Eppendorf tube. The mixture was vortex-mixed and 
sonicated for 10 min to improve the precision of the 
extraction procedure before centrifugation (7000 g 
for 5 min). The supernatant was then transferred to a 
sample vial for LC-MS/MS analysis. A series of aqueous 
calibrators, ranging from 0 to 100 μ mol/L was used.
Statistical analysis
Data were analyzed using SPSS version 17. 
Data were expressed as mean ± standard deviation 
for quantitative variables, number, and percentage 
for qualitative ones. Comparisons between the 
experimental groups were done by the Student’s t-test. 
Pearson’s correlation was performed to correlate the 
individual variables. p < 0.05 was considered to be 
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statistically significant and p – 0.001 was considered to 
be statistically highly significant.
Results
Detailed patient characteristics were given in 
Table 1.
Comparison between HD patients and 
controls as regards to serum hepcidin and anemia 
markers levels. Statistically significant increases 
in serum levels of hepcidin (100.7 ± 0.99 ng\ml vs. 
77.43 ± 0.8 ng\ml, p = 0.000) and serum levels of 
ferritin (968.10 ± 5.3 ng\ml vs. 674.00 ± 4.56 ng\ml, 
p = 0.000) were found in HD children as compared to 
healthy controls. However, serum iron levels (65.62 
± 0.62 mg/l vs. 90.4 ± 0.73 mg/l, p = 0.000) and 
serum TIBC (234 ± 0.67 mg/l vs. 258 ± 0.89 mg/l, p = 
0.000) showed statistically significant decrease in HD 
children as compared to healthy controls Figure 1.
Comparison between HD patients and 
controls as regards to serum carnitine and 
inflammatory markers levels
Statistically significant increase in serum 
levels of hs-CRP (3.94 ± 0.19 mg/l vs. 1.36 ± 
0.07 mg/l, p = 0.04) was found in HD children as 
compared to healthy controls. However, serum 
levels of carnitine (29.59 ± 2.46 μmol/L vs. 36 ± 
2.39 μmol/L, p = 0.000), serum levels of hemoglobin 
(11.41 ± 0.53 g/dl vs. 14.23 ± 0.75 g/dl, p = 0.000), 
and serum levels of albumin (3.62 ± 0.13 g/dl vs. 
4.92 ± 0.39 g/dl, p = 0.000) showed statistically 
significant decreases in HD children as compared to 
healthy controls Figure 2.
Pearson’s correlations between different 
studied biochemical parameters in HD children 
were shown in Table 2
A negative correlation was found between serum 
hepcidin levels and serum albumin levels (r = –0.371, 
p = 0.011), but a positive one was found between serum 
hepcidin levels and serum hs-CRP levels (r = 0.059, 
p = 0.042) in HD children. Positive correlations were 
present between serum carnitine levels and both of 
serum ferritin levels and serum iron levels (r = 0.644, p = 
0.045 and r = 0.651, p = 0.042, respectively). Considering 
serum ferritin levels, positive correlations were observed 
with serum albumin levels (r = 0.682, p = 0.03) and 
serum TIBC levels (r = 0.652, p = 0.03).
No correlation was found between serum hepcidin 
levels and serum carnitine levels (r = 0.052, p = 0.887).
Figure 1: Comparison between hemodialysis patients and controls as 
regards to serum hepcidin and anemia markers levels. Serum levels 
of ferritin (968.10 ± 5.3 ng\ml vs. 674.00 ± 4.56 ng\ml, p = 0.000), 
serum iron levels (65.62 ± 0.62 mg/l vs. 90.4 ± 0.73 mg/l, p = 0.000), 
serum levels of TIBC (234 ± 0.67 mg/l vs. 258 ± 0.89 mg/l, p = 0.000), 
and serum levels of hepcidin (100.7 ± 0.99 ng\ml vs. 77.43 ± 
0.8 ng\ml, p = 0.000). p < 0.05 was considered to be statistically 
significant and p ˂ 0.001 was considered to be statistically highly 
significant. TIBC: Total iron-binding capacity
Discussion
In the present study, hepcidin revealed a 
statistically significant increase in children on HD 
Table 1: Descriptive and biochemical characteristics of the 
studied subjects
Parameters Controls (n=30) Patients (n=30) p-value
Age (years) 8.7 ± 0.51 10.62 ± 0.49 0.14
BMI (kg/m2) 20.88 ± 1.1 18.89 ± 0.87 0.17
Sex (M/F) % 20/10 23/7 0.31
SBP (mmHg) 94.55 ± 9.80 125.13 ± 16.36 0.01*
DBP (mmHg) 60.59 ± 10.11 83.13 ± 12.76 0.01*
Urea (mg/dl) 7.80 ± 2.64 70.56 ± 19.61 0.02*
Data are mean ± SD, number (%) or range as applicable. Significance was estimated using independent 
t-test, BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure.*p – 0.05, 
**p – 0.001. p < 0.05 was considered to be statistically significant and p – 0.001 was considered to be 
statistically highly significant.
Figure 2: Comparison between hemodialysis patients and controls 
as regards to serum carnitine and inflammatory markers levels. 
Serum levels of carnitine (29.59 ± 2.46 μmol/L vs. 36 ± 2.39 μmol/L, 
p = 0.000), serum levels of hemoglobin (11.41 ± 0.53 g/dl vs. 14.23 ± 
0.75 g/dl, p = 0.000), serum levels of albumin (3.62 ± 0.13 g/dl vs. 4.92 
± 0.39 g/dl, p = 0.000), and serum levels of hs-CRP (3.94 ± 0.19 mg/l 
vs. 1.36 ± 0.07 mg/l, p = 0.04). p < 0.05 was considered to be 
statistically significant and p ˂ 0.001 was considered to be statistically 
highly significant. hsCRP: High sensitivity C-reactive protein
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when compared to their healthy controls. Moreover, 
hepcidin levels were positively correlated with hs-CRP 
and negatively correlated with albumin, which was in 
agreement with Zaritsky et al. [13]. Hepcidin levels are 
regulated by the erythropoietic activity and iron status [14]. 
It is now well known that hepcidin levels are increased 
by inflammation and reduced by anemia and hypoxia. 
Renal anemia is considered a special form of anemia of 
inflammation [14]. The decrease in both iron uptake from 
the small intestine and release of iron from macrophages 
as well as decreased placental iron transport was 
recorded to be associated with increased hepcidin levels. 
Hepcidin levels are predicted to be increased in patients 
with ESRD due to restricted hepcidin excretion in urine, 
tissue iron overload, and inflammation [21-24]. 
In this study, we found decreased levels of serum 
iron and TIBC in children on HD. Nevertheless, serum 
ferritin levels were found to be increased in this group. 
These findings were consistent with previous studies 
on patients with CKD [14], [18]. Multiple mechanisms 
are incorporated in the disruption of iron metabolism 
in advanced kidney diseases [15]. Iron deficiency may 
be caused by high hepcidin concentrations [12], as a 
result of decreased iron absorption [25], in addition 
to increased iron losses, mainly from gastrointestinal 
losses [26]. Iron binding effects in intra- and extracellular 
spaces of iron-chelating agents might be of benefit in 
renal injury [27].
High ferritin levels found in these HD 
children might be due to functional iron deficiency 
or reticuloendothelial blockade [14]. Serum ferritin 
is a good indicator of iron stores when there is no 
inflammation. In the presence of inflammation, hepcidin 
stimulates ferritin production and macrophages, prolific 
secretors of serum ferritin, trap iron inside it [28]. Many 
previous studies support the idea that current markers 
of iron metabolism such as transferrin concentration and 
ferritin do not predict iron status carefully [14]. These 
conventional markers had some limitations as it can be 
affected by age, gender, inflammation, and nutritional 
factors. It was reported that the determination of hepcidin 
concentrations together with conventional markers 
of iron metabolism could improve the identification of 
patients with iron deficiency by 26.1% [29].
In this study, hsCRP was measured as the 
most significant marker of inflammation and was found 
to be higher HD children than in healthy controls, and 
these levels were found to be significantly correlated 
with serum hepcidin. It is well known that hepcidin 
synthesis is induced by inflammation, a process that 
is mediated by IL-6. CKD patients undergoing HD 
have high levels of inflammatory markers such as 
CRP, IL6, tumor necrosis factor-alpha, and interferon-c 
accompanied with low serum levels of albumin which 
was in accordance with the current study [30].
The present study showed decreased serum 
carnitine levels in children on HD and was found to be 
positively correlated with serum iron levels. Previous 
studies had been concluded a high prevalence of 
carnitine deficiency in patients on HD [17], [18], [19], [20]. 
Carnitine loss through dialysis machines was concluded 
to be associated with the deficiency of carnitine in HD 
patients. Loss of carnitine during dialysis, in addition to 
the reduced renal synthesis and decreased intake of 
meat and dairy products (dietary source of carnitine), 
had been proposed as a cause of carnitine deficiency 
in the ESRD population [31], [32]. Several studies had 
concluded that carnitine deficiency was associated 
with anemia [17], [33], [34]. Carnitine contributes to 
erythrocyte membranes stabilization, allowing an 
improvement of their deformability [17], [33], [34]. 
The National Kidney Foundation had proposed in a 
conference report that carnitine deficiency in patients on 
HD was a dialysis-related carnitine disorder [35]. They 
recommended carnitine supplementation for patients 
on HD who have erythropoietin-resistant anemia, 
hypotension during HD sessions, cardiac dysfunction, 
and muscle weakness [35]. Therefore, evaluation of 
carnitine deficiency together with appropriate carnitine 
supplementation is important for treating children on HD.
Conclusions
Serum hepcidin levels were shown to be 
increased in children on HD. It may be a more useful 
biomarker of anemia in these patients. Serum hepcidin 
provides a piece of good utility information about the iron 
status during inflammation as compared with conventional 
markers of iron status. Carnitine deficiency was found in 
children on HD and was significantly correlated with the 
iron levels. Further studies on the efficacy of carnitine 
treatment for children on HD with carnitine deficiency and 
its effect on anemia need to be done.
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Table 2: Pearson’s correlations between different studied biochemical parameters in HD children
Parameters Carnitine Hepcidin Hemoglobin Albumin hsCRP Ferritin Iron TIBC
r p r p r p r p r p r p r p r p
Carnitine - - 0.052 0.887 –0.155 0.670 –0.0371 0.291 0.059 0.870 0.644* 0.045 0.651* 0.042 –0.102 0.780
Hepcidin 0.052 0.887 - - –0.155 0.836 –0.371 0.011 0.059 0.042 –0.644* 0.363 0.651* 0.869 –0.102 0.443
Pearson’s correlation coefficient was used. p < 0.05 was considered to be statistically significant and p–0.001 was considered to be statistically highly significant. hsCRP: High sensitivity C-reactive protein, TIBC: Total iron-
binding capacity.
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